BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
8.19 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | BioCryst Pharmaceuticals, Inc. |
| Symbool | BCRX |
| Munteenheid | USD |
| Prijs | 8.19 |
| Beurswaarde | 1,719,244,800 |
| Dividendpercentage | 0% |
| 52-weken bereik | 6.02 - 11.31 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Jon P. Stonehouse |
| Website | https://www.biocryst.com |
An error occurred while fetching data.
Over BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)



